Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $4 | $5 | $1 |
| % Growth | -74.1% | -15.3% | 339.4% | – |
| Cost of Goods Sold | $3 | $0 | $0 | $0 |
| Gross Profit | -$2 | $4 | $5 | $1 |
| % Margin | -168% | 100% | 100% | 100% |
| R&D Expenses | $240 | $169 | $130 | $84 |
| G&A Expenses | $100 | $58 | $42 | $25 |
| SG&A Expenses | $100 | $58 | $42 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | $0 | $0 | $0 |
| Operating Expenses | $337 | $227 | $173 | $109 |
| Operating Income | -$339 | -$223 | -$168 | -$108 |
| % Margin | -32,613.5% | -5,547.2% | -3,544.1% | -9,990.9% |
| Other Income/Exp. Net | $40 | $8 | $4 | $0 |
| Pre-Tax Income | -$298 | -$215 | -$164 | -$108 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$298 | -$215 | -$164 | -$108 |
| % Margin | -28,720.7% | -5,345.9% | -3,460.4% | -9,985.3% |
| EPS | -3.69 | -3.69 | -3.15 | -2.8 |
| % Growth | 0% | -17.1% | -12.5% | – |
| EPS Diluted | -3.69 | -3.69 | -3.15 | -2.8 |
| Weighted Avg Shares Out | 81 | 58 | 52 | 38 |
| Weighted Avg Shares Out Dil | 81 | 58 | 52 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $41 | $13 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $1 | $1 | $1 |
| EBITDA | -$336 | -$222 | -$167 | -$107 |
| % Margin | -32,345.4% | -5,519.8% | -3,523.3% | -9,905.4% |